<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133405</url>
  </required_header>
  <id_info>
    <org_study_id>13733</org_study_id>
    <secondary_id>I4O-MC-BACA</secondary_id>
    <nct_id>NCT01133405</nct_id>
  </id_info>
  <brief_title>A Safety Study of LY2886721 Single Doses in Healthy Subjects</brief_title>
  <official_title>Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of
      LY2886721 single doses, how the body handles the drug, and the drug's effect on the body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 study with 2 parts, both in healthy subjects. Part 1 is a subject- and
      investigator-blind, placebo-controlled, randomized, 3-period, crossover study. Part 1 will
      assess the safety and tolerability of LY2886721 single doses, how the body handles the drug,
      and the drug's effect on the body. Part 2 is a subject- and investigator-blind,
      placebo-controlled, randomized study to assess the safety and tolerability of an LY2886721
      single dose, how the body handles the drug, and the drug's effect on the body including in
      cerebrospinal fluid.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Clinically Significant Effects</measure>
    <time_frame>Predose to 10-14 days after final dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of LY2886721 (Cmax)</measure>
    <time_frame>Predose and up to Day 8 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of LY2886721 (AUC)</measure>
    <time_frame>Predose and up to Day 8 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic biomarker plasma Abeta 1-40 concentration</measure>
    <time_frame>Predose and up to Day 8 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid (CSF) concentration of LY2886721 (Cmax) (Part 2 only)</measure>
    <time_frame>Predose and up to 36 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid (CSF) Pharmacodynamic biomarker Abeta 1-40 concentration (Part 2 only)</measure>
    <time_frame>Predose and up to 36 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid (CSF) concentration of LY2886721 (AUC) (Part 2 only)</measure>
    <time_frame>Predose and up to 36 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>LY2886721 Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 3 single doses will be administered over 3 periods (each period is 8 days) in a crossover fashion either LY:LY:LY or LY:LY:Placebo in random order with variable doses ranging from 1 mg up to 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose in up to 1 period (the period is 8 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2886721 Part 2 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY2886721, dose determined by Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2886721 Part 2 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY2886721, dose determined by Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2886721</intervention_name>
    <description>Oral capsules</description>
    <arm_group_label>LY2886721 Part 1</arm_group_label>
    <arm_group_label>LY2886721 Part 2 low dose</arm_group_label>
    <arm_group_label>LY2886721 Part 2 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral capsules</description>
    <arm_group_label>Placebo Part 1</arm_group_label>
    <arm_group_label>Placebo Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and nonchild-bearing potential women

          -  20 years or older

          -  Body mass index between 18-32 kg/m2

        Exclusion Criteria:

          -  Taking over-the-counter or prescription medication with the exception of vitamins or
             minerals or stable doses of thyroid or estrogen hormone replacement

          -  Smoke more than 10 cigarettes per day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <last_update_submitted>November 4, 2010</last_update_submitted>
  <last_update_submitted_qc>November 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

